HKU Scholars Hub: Browsing DSpace

Browsing by Author Yap, YS

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 5 to 12 of 12 < previous

	Title	Author(s)	Issue Date	Views
	Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) Proceeding/Conference:Annals of Oncology	Yap, YS Su, F Joshi, /M Chiu, WYJ Masuda, N Ito, Y Ishikawa, T Aruga, T Kim, SJ Deore, U Babbar, N Balbin, A	2021	13
	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer Journal:Future Oncology	Iwata, H Masuda, N Kim, SB Inoue, KSL Rai, YS Fujita, T Chiu, WYJ Ohtani, S Takahashi, M Miyaki, TY Lu, YS Xu, B Yap, YS Bustam, A Yao, B Zhang, B Bryce, R Chan, A	2019	72
	Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: exploratory analyses from the phase III ExteNET trial Proceeding/Conference:San Antonio Breast Cancer Congress (SABCS)	Iwata, H Masuda, N Kim, S-B Inoue, K Rai, TY Fujita, TCC Shen, Z-Z Chiu, WYJ Ohtani, S Takahashi, M Yamamoto, N Miyaki, T Sun, Q Lu, YS Xu, B Yap, YS Bustam, A Yee, Y Zhang, B Bryce, R Chan, A	2017	60
	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Journal:Journal of Clinical Oncology	Saura, C Oliveira, M Feng, YH Dai, MS Chen, SW Hurvitz, SA Kim, SB Moy, B Delaloge, S Gradishar, W Masuda, N Palacova, M Trudeau, ME Mattson, J Yap, YS V, MF De Laurentiis, M Yeh, YM Chang, HT Yau, T Wildiers, H Haley, B Fagnani, D Lu, YS Crown, J Lin, J Takahashi, M Takano, T Yamaguchi, M Fujii, T Yao, B Bebchuk, J Keyvanjah, K Bryce, R Brufsky, A The NALA Investigators	2020	35
	Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors Journal:Current Medical Research and Opinion	Dawood, S Chiu, JWY Huang, CS Nag, S Sookprasert, A Yap, YS Md Yusof, M	2020	25
	Phase Ib study of ribociclib plus letrozole in a subset of Asian patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer Proceeding/Conference:Annals of Oncology	Yap, YS Ito, Y Bornstein, O Han, Y Samant, TS Liu, X Chiu, WYJ	2017	65
	Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer Journal:Cancer Science	Yap, YS Chiu, J Ito, Y Ishikawa, T Aruga, T Kim, SJ Toyama, T Saeki, T Saito, M Gounaris, I Su, F Ji, Y Han, Y Gazdoiu, M Masuda, N	2020	30
	Upregulation of Immune Response Biomarkers by Ribociclib Plus Endocrine Therapy in Paired Tumor Samples From Phase I Studies Proceeding/Conference:San Antonio Breast Cancer Symposium 2021	Juric, D Ma, C Tiedt, R Yap, YS Chiu, WYJ Munster, P Ismail-Khan, R Garcia-Estevez, L Mayer, IA Becerra, C Solovieff, N Lteif, A Su, F Lu, YS	2021	8

Showing results 5 to 12 of 12 < previous